A propensity score-weighted comparison between adalimumab originator and its biosimilars, ABP501 and SB5, in inflammatory bowel disease: a multicenter Italian study

Brigida Barberio,Linda Cingolani,Cristina Canova,Giulia Barbieri,Renato Sablich,M.T. Urbano,Lorenzo Bertani,Francesco Costa,Giorgia Bodini,Maria Giulia Demarzo,A. Ferronato,Andrea Buda,Piera Melatti,Davide Massimi,Edoardo Savarino,Fabiana Zingone

A propensity score-weighted comparison between adalimumab originator and its biosimilars, ABP501 and SB5, in inflammatory bowel disease: a multicenter Italian study

2021

Brigida Barberio
Linda Cingolani
Cristina Canova
Giulia Barbieri
Renato Sablich
M.T. Urbano
Lorenzo Bertani
Francesco Costa
Giorgia Bodini
Maria Giulia Demarzo
A. Ferronato
Andrea Buda
Piera Melatti
Davide Massimi
Edoardo Savarino
Fabiana Zingone

Background:Adalimumab is an effective and safe biological drug for the treatment of inflammatory bowel disease (IBD). Nowadays, several biosimilar agents are available, but data regarding their eff...

Keywords:

Biosimilar
Drug
Propensity score matching
Medicine
Adalimumab
Internal medicine
Crohn's disease
Inflammatory bowel disease
Ulcerative colitis

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations